262 results
8-K
EX-99.1
GOVX
Geovax Labs Inc
1 Mar 24
GeoVax Reports 2023 Year-End Financial Results
4:09pm
of manufacturing materials for use in our clinical trials, technology license fees, personnel costs, costs of preclinical research activities and higher travel
POS AM
GOVX
Geovax Labs Inc
1 Mar 24
Prospectus update (post-effective amendment)
4:04pm
supplies of our products, our strategy is to rely on established, recognized third-party contract manufacturers to produce materials needed for research … contractors are generally available in the United States and Europe for manufacture of materials for clinical trial evaluation, however, it may be difficult
POS AM
GOVX
Geovax Labs Inc
1 Mar 24
Prospectus update (post-effective amendment)
4:04pm
products, our strategy is to rely on established, recognized third-party contract manufacturers to produce materials needed for research and clinical … are generally available in the United States and Europe for manufacture of materials for clinical trial evaluation, however, it may be difficult to replace
POS AM
46awu4ohc9qa9y42nyb
1 Mar 24
Prospectus update (post-effective amendment)
4:03pm
POS AM
hyjof7 g321k6g9ugr
1 Mar 24
Prospectus update (post-effective amendment)
4:03pm
424B3
ogmz 89q6b9drtyab
12 Jan 24
Prospectus supplement
4:00pm
8-K
EX-10.1
3p5e6t wgwudrdcz20li
4 Dec 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
0mabu5vge8rq
9 Nov 23
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
12:40pm
424B3
qlkq7y1fjwzloyaw
8 Nov 23
Prospectus supplement
4:04pm
424B3
0fwkzvndaj 7dp
8 Nov 23
Prospectus supplement
4:03pm
424B3
n9okg7g
8 Nov 23
Prospectus supplement
4:01pm
8-K
EX-99.1
041i2
10 Aug 23
GeoVax Reports 2023 Second Quarter Financial Results
9:45am